home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Potentially New Treatment For Liver Cirrhosis

  July, 2 2001 2:13
your information resource in human molecular genetics
Potentially New Treatment For Liver Cirrhosis

Cirrhosis of the liver, which usually develops as a long-term consequence of chronic alcoholism or viral hepatitis, is associated with damage to liver tissue and loss of liver function, fluid accumulation in the abdomen (ascites), increased pressure in the blood vessels (portal hypertension) and vasodilation of the systemic circulation resulting in low blood pressure.

The vasodilated state of blood vessels in the periphery markedly increases mortality, but conventional medications that should be able to counter vessel dilation do not work on cirrhotic vessels. Now, a team of scientists from the US National Institute on Alcohol Abuse & Alcoholism has discovered that vasodilation in cirrhosis is mediated through receptors for endogenous cannabinoids (specifically CB1) and can be reduced in a rat model using a compound that blocks these receptors - SR141716A (Nature Medicine, Vol. 7, No. 7, 01 July 2001, page 827). Additionally, they have discovered that cirrhotic human livers contain increased numbers of cannabinoid receptors.

The findings point to endogenous cannabinoids such as anadamide as being responsible for the cirrhotic vasodilation. If this proves to be true in humans, the authors write, “…antagonists of these receptors might offer a therapeutic approach to the management of patients with advanced liver cirrhosis…”

Dr. George Kunos
National Institute on Alcohol Abuse & Alcoholism
National Institutes of Health
Bethesda, MD
Tel: (+1) 301-402-1226
Fax: (+1) 301-443-5894

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.